Calidi Biotherapeutics, Inc. 8-K

What Happened Calidi Biotherapeutics, Inc. filed a Current Report on Form 8‑K (filed Feb 10, 2026) disclosing that it made an updated corporate presentation available on its website on February 6, 2026. The presentation was furnished with the filing as Exhibit 99.1. The company stated that by furnishing the presentation it is not admitting that any information contained therein is material solely due to Regulation FD.

Key Details

• Updated presentation posted on the company website on February 6, 2026.
• Presentation furnished with the 8‑K as Exhibit 99.1 and incorporated by reference.
• Company included the standard Regulation FD language disclaiming an admission of materiality.

Why It Matters This 8‑K makes the company’s latest investor presentation publicly available, so investors can review Calidi’s most recent corporate information and messaging directly from the source. The filing does not disclose new financial results or executive changes; instead it documents the public release of the presentation and the company's Regulation FD position. Investors seeking updates on strategy, pipeline, timing, or financials should review the posted presentation and any other SEC filings for material disclosures.